Literature DB >> 28848912

The COPD Pipeline XXXIII.

Nicholas Gross1.   

Abstract

Year:  2017        PMID： 28848912      PMCID： PMC5560251          DOI： 10.15326/jcopdf.4.1.2016.0178

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN： 2372-952X


× No keyword cloud information.
  4 in total

1.  Treatment with monoclonal antibodies against Clostridium difficile toxins.

Authors:  Israel Lowy; Deborah C Molrine; Brett A Leav; Barbra M Blair; Roger Baxter; Dale N Gerding; Geoffrey Nichol; William D Thomas; Mark Leney; Susan Sloan; Catherine A Hay; Donna M Ambrosino
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

2.  Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.

Authors:  Henrik Watz; Helen Barnacle; Benjamin F Hartley; Robert Chan
Journal:  Lancet Respir Med       Date:  2013-12-05       Impact factor: 30.700

3.  Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Authors:  Nicola A Hanania; Michael Noonan; Jonathan Corren; Phillip Korenblat; Yanan Zheng; Saloumeh K Fischer; Melissa Cheu; Wendy S Putnam; Elaine Murray; Heleen Scheerens; Cecile T J Holweg; Romeo Maciuca; Sarah Gray; Ramona Doyle; Dana McClintock; Julie Olsson; John G Matthews; Karl Yen
Journal:  Thorax       Date:  2015-05-22       Impact factor: 9.139

4.  Mucolytic Effectiveness of Tyloxapol in Chronic Obstructive Pulmonary Disease - A Double-Blind, Randomized Controlled Trial.

Authors:  Martin Koppitz; Charlotte Eschenburg; Emilia Salzmann; Martin Rosewich; Ralf Schubert; Stefan Zielen
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240
  4 in total
  1 in total

Review 1.  Medication Regimens for Managing COPD Exacerbations.

Authors:  Nirupama Putcha; Robert A Wise
Journal:  Respir Care       Date:  2018-06       Impact factor: 2.258
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.